{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-018954","form_type":"8-K/A","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2026-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.156242+00:00","generated_at":"2026-05-15T04:14:38.904442+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Indaptus Therapeutics Appoints Tim Ruan and Johnny Fox Arrowsmith as Independent Directors; Matthew McMurdo Resigns","bullets":["Tim Ruan, 40, CFO of Ocumension Therapeutics and former Executive Director at Goldman Sachs, appointed as Class II director.","Dr. Johnny Fox Arrowsmith (Yi Zhang), 48, partner at JunHe and registered patent attorney, appointed as Class II director.","Matthew McMurdo resigned as director on April 22, 2026; resignation not due to any disagreement with company.","Each new director receives annual cash retainer of $30,000, payable quarterly, plus expense reimbursement and indemnification.","Ruan appointed to Audit Committee; Arrowsmith appointed to Nominating Committee. New directors effective April 22, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-018954","json":"https://secwatch.observer/filing/0001493152-26-018954.json","markdown":"https://secwatch.observer/filing/0001493152-26-018954.md","text":"https://secwatch.observer/filing/0001493152-26-018954.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315226018954/0001493152-26-018954-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315226018954/form8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-15T04:14:38.904442+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}